Navigation Links
Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
Date:2/18/2008

CAMBRIDGE, England, February 18 /PRNewswire/ -- Ranier Technology, a Cambridge UK based spinal implant development company, has secured an GBP8 million ($16 million) investment from new and existing investors to further develop and commercialise its motion preserving spinal implant products. The investment was made by Alliance Trust Equity Partners (ATEP) and First Ventures to fund the clinical testing and European launch of CAdisc L, the lumbar version of Ranier's compliant replacement spinal disc. In addition, the funding will enable the company to further develop and test CAdisc C - Ranier's total disc replacement for the cervical spine.

Commenting, Dr Geoffrey Andrews CEO and Founder of Ranier said, "We are delighted to have secured this funding from both new and existing high quality investors, and we warmly welcome ATEP as a new investor. This investment is strong validation of our CAdisc product technology and the exciting role our products will play in the burgeoning global spinal disc markets".

Ranier's CAdisc total disc replacement devices are designed to replace diseased spinal discs in both the lumbar (lower back) and cervical (neck) regions of the spine and to bring relief and a normal quality of life for younger patients (20 - 60 years old) who suffer debilitating pain from degenerative disc disease, and who do not wish to tolerate a major degradation to their life style.

The replacement spinal disc market is set to grow to over $2 billion per annum by 2015 and Ranier anticipates that its CAdisc products are well placed to take a significant proportion of that market. The CAdisc is a unique, entirely polymeric, shock absorbing design which allows the natural bio-mechanics of the spinal disc to be restored without the use of metal or sliding surfaces. CAdisc has been designed to be a highly durable, entirely MRI compatible implant, capable of protecting adjacent discs from accelerated degeneration observed with non-compliant
'/>"/>

SOURCE Ranier Technology Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Religion colors Americans views of nanotechnology
2. National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights
3. Technology Transforms Market Research in Pharmaceutical Industry
4. ZyGEM Appoints Leading Biotechnology Expert to Head Clinical Advisory Board
5. New Technology for Early Detection of Lung Cancer Selected for Clinical Study With Veterans
6. Fiber-based nanotechnology in clothing could harvest energy from physical movement
7. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
8. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
9. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
10. Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center
11. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... A research team led by group leader Yung-Eun ... technology to synthesize sulfur-doped and nitrogen-doped graphenes which ... secondary batteries and fuel cells. Yung-Eun Sung is ... Nanoparticle Research at Institute for Basic Science* (IBS) ... , This achievement has great significance with regards ...
(Date:7/24/2014)... -- Research and Markets has announced the ... report to their offering.  ... in vitro growth of plant or animal cells for ... production. Cell culture is a crucial step in tissue ... culture consumables are necessary for the in vitro production ...
(Date:7/24/2014)... 2014  CorMedix Inc. (NYSE MKT: CRMD), a ... products for the prevention and treatment of cardiorenal ... on July 18, 2014 from the NYSE MKT ... CorMedix plan to regain compliance with continued listing ... NYSE-MKT is continuing the Company,s listing and has ...
(Date:7/24/2014)... PRINCETON, N.J. , July 24, 2014 /PRNewswire/ ... largest provider of regulatory and ethical review services ... acquired Alliance Biosciences. Formerly a division of ... Biosciences was the leading biosafety and biosecurity consulting ... . With this addition, WCG,s biosafety division – ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... data from Phase 3 European clinical ... pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), ... prevalent serotypes associated with pneumococcal disease (PD), the leading cause ... , , The Phase 3 data presented at ...
... Syngenta today announced that it has ... antitoxin crop protection technology to the company,s portfolio. Circle ... reducing aflatoxin, a toxin that can develop in crops such ... , , "The acquisition of this technology adds ...
... ... Stage Solutions, Inc. has expanded its financial services offerings to further meet ... launched three new services: First, CFO on Demand - NSS partners with ... Strategic Finance - the Next Stage Solutions team equips its clients with ...
Cached Biology Technology:New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 2New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 4New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 5New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 6Syngenta Acquires Innovative Bio-Control Technology to Improve Usable Crop Yields 2Syngenta Acquires Innovative Bio-Control Technology to Improve Usable Crop Yields 3Next Stage Solutions Announces Three New Financial Services For Emerging Business 2Next Stage Solutions Announces Three New Financial Services For Emerging Business 3
(Date:7/25/2014)... for Medical Research have identified the functions of ... to triggering the mating process in mice. , They ... detect pheromones that indicate when a female is present. ... the female mouse is ovulating and ready to mate. ... Stowers, researchers believe mice developed this system through evolution ...
(Date:7/25/2014)... have detected an unknown interaction between microorganisms and salt. ... a droplet of salt water and is left to ... biomineralogical biosaline 3D morphologically complex formations, where they hibernate. ... The discovery was made by chance with a home ... Astrobiology journal and may help to find signs ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
Breaking Biology News(10 mins):It takes two to court 2It takes two to court 3Bacteria manipulate salt to build shelters to hibernate 2NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2
... tissues and organs. Because these cells are able to grow ... they hold the key to groundbreaking new therapies. To help ... found a new way to culture cells in 3D a ... body grow and divide in a 3D environment, especially when ...
... of people suffer from Parkinson,s disease, a disorder of ... time. As the world,s population ages, it,s estimated that ... sharply. Yet despite several effective therapies that treat Parkinson,s ... it,s not known what exactly causes the disease, evidence ...
... now, it was presumed that the last glacial period ... return of milder weather began and melted away the ... now disproved by research headed by Professor Eske Willerslev ... Laura Parducci from the University of Uppsala, Sweden, and ...
Cached Biology News:Parkinson's disease stopped in animal model 2Parkinson's disease stopped in animal model 3Sturdy Scandinavian conifers survived Ice Age 2Sturdy Scandinavian conifers survived Ice Age 3
The PxE Thermal Cycler (PxE) is a licensed 96 well PCR machine, developed to provide all fundamental features for value for money thermal cycling....
PxE thermal Cycler. 0.5ml block holds 48 0.5 ml tubes or 96 0.3 ml tubes. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User frien...
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
A Highly Purified, Cost-Effective Taq DNA Polymerase...
Biology Products: